drugset / Trial / NCT01426100

CKD-828 Telmisartan Non-Responder Trial

NCT01426100

Phase 3 Completed 183 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupTriple-blindTreatment

Summary

The aim of the present study is to evaluate the efficacy and safety of two dose combination of Telmisartan/S-Amlodipine (40/2.5mg and 40/5mg) compared with telmisartan monotherapy (80mg) in hypertensive patients inadequately controlled by telmisartan monotherapy.

Timeline

Start
2011-08
Primary completion
2012-05
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Subject S-amlodipine Unknown 2.5 mg
Subject S-amlodipine Unknown 5 mg
Comparator Telmisartan Other / unclassified 40 mg
Comparator Telmisartan Other / unclassified 80 mg

Indications